Mineralocorticoid receptor antagonists detailed in Suzhong Pharmaceutical patent
Feb. 21, 2024
A Nanjing Suzhong Pharmaceutical Research Co. Ltd. and Suzhong Pharmaceutical Group Co. Ltd. patent describes phenyl-substituted dihydronaphthyridine compounds acting as mineralocorticoid receptor (MR) antagonists potentially useful for the treatment of aldosteronism, cirrhosis, diabetic nephropathy, heart failure, hypertension, myocardial infarction, renal failure and stroke.